Stanford Medicine-led research in mice indicates that inhibiting the LRRK2 enzyme could stabilize patients with a type of Parkinson’s disease.
A leader in the biomedical revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies.